Back

Efficacy and safety of sacubitril/valsartan (LCZ696) in reducing adverse cardiovascular events and controlling hypertension among asians: a meta-analysis of randomised controlled trials

21 May 2022 (08:30 - 18:50)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Pharmacology and other topics Cardiovascular Pharmacotherapy HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Patrick Vera Cruz

St. Luke's Medical Center, Quezon (Philippines)

30 More presentations in this session

Presentation thumbnail
Role of empagliflozin in diabetic patient with acute myocardial infarction who undergone percutaneous coronary intervention
Presentation thumbnail
Recovery of left ventricular ejection fraction in patients treated with sacubitril/valsartan
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Levosimendan bridge to therapy optimization
Doctor C. Moliner-Abos (Barcelona, ES)
Abstract Slides
Presentation thumbnail
ORal anti-coagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the ORIGAMI pilot investigation
Doctor D. D'Amario (Novara, IT)
Abstract Slides
Presentation thumbnail
Beta-blockers and ivabradine titration in HF patients with LV only fusion pacing CRT
Doctor C. Vacarescu (Timisoara, RO)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Pharmacology and other topics

The Event

Event poster

Heart Failure 2022

21 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources